SCHEMBL4903155

SCHEMBL4903155

CCc1ccc(S(=O)(=O)NCCc2ccc(Oc3ccc(C(F)(F)F)cc3)cc2)cc1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 4/20 0.48
LTA4H P09960 1/20 0.47
EPHX2 P34913 1/20 0.47
ALDH1A1 P00352 6/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
MAPT P10636 2/20 0.43
POLB P06746 1/20 0.42
MAPK1 P28482 1/20 0.42
KMT2A Q03164 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
LMNA P02545 2/20 0.42
TBXA2R P21731 1/20 0.42
TBXAS1 P24557 1/20 0.42
RORC P51449 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4900950 0.92 ADAMTS4 (0.49) AKR1C3KMT2ATBXA2RTBXAS1
SCHEMBL4895673 0.91 ALDH1A1 (0.46) AKR1C3LTA4HEPHX2ALDH1A1SMN1; SMN2
SCHEMBL4899868 0.91 AKR1C3 (0.48) AKR1C3LTA4HEPHX2ALDH1A1SMN1; SMN2
SCHEMBL4894652 0.89 LMNA (0.50) AKR1C3LTA4HEPHX2ALDH1A1SMN1; SMN2
SCHEMBL4898067 0.89 ALDH1A1 (0.57) AKR1C3ALDH1A1SMN1; SMN2MAPTPOLB
SCHEMBL4906430 0.89 AKR1C3 (0.56) AKR1C3ALDH1A1SMN1; SMN2MAPTPOLB
SCHEMBL4904654 0.88 ALDH1A1 (0.52) AKR1C3ALDH1A1SMN1; SMN2POLBMAPK1
SCHEMBL4895722 0.87 AKR1C3 (0.55) AKR1C3ALDH1A1SMN1; SMN2MAPTKMT2A
SCHEMBL4900980 0.85 MAPK1 (0.49) AKR1C3ALDH1A1SMN1; SMN2MAPTPOLB
SCHEMBL4895103 0.85 TP53 (0.49) AKR1C3ALDH1A1SMN1; SMN2MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765796-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS Pfizer Products Inc. (US) 2007-03-28 EP claimed
WO-2006003495-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER PRODUCTS INC. (US) 2006-01-12 WO claimed
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-12-29 US claimed
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 US disclosed
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 US disclosed
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 US disclosed
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PPARA, PPARG, PPARD AKR1C3 1645/4885LTA4H 2962/4885EPHX2 3463/4885
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PPARA, PPARG, PPARD AKR1C3 1645/4885LTA4H 2962/4885EPHX2 3463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.